@article{d07dd87a9c5245c9a668901dad70a4aa,
title = "Head and Neck Cancers, Version 1.2022 Featured Updates to the NCCN Guidelines",
abstract = "The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer, salivary gland cancer, and mucosal melanoma (MM) are also addressed. The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel{\textquoteright}s most recent recommendations regarding management of HPV-positive oropharynx cancer and ongoing research in this area.",
author = "Caudell, {Jimmy J.} and Gillison, {Maura L.} and Ellie Maghami and Sharon Spencer and Pfister, {David G.} and Douglas Adkins and Birkeland, {Andrew C.} and Brizel, {David M.} and Busse, {Paul M.} and Cmelak, {Anthony J.} and Colevas, {A. Dimitrios} and Eisele, {David W.} and Thomas Galloway and Geiger, {Jessica L.} and Haddad, {Robert I.} and Hicks, {Wesley L.} and Hitchcock, {Ying J.} and Antonio Jimeno and Debra Leizman and Mell, {Loren K.} and Mittal, {Bharat B.} and Pinto, {Harlan A.} and Rocco, {James W.} and Rodriguez, {Cristina P.} and Savvides, {Panayiotis S.} and David Schwartz and Shah, {Jatin P.} and David Sher and {St. John}, Maie and Weber, {Randal S.} and Gregory Weinstein and Frank Worden and Bruce, {Justine Yang} and Yom, {Sue S.} and Weining Zhen and Burns, {Jennifer L.} and Darlow, {Susan D.}",
note = "Funding Information: This activity is supported by educational grants from AstraZeneca; BeiGene; Exact Sciences; Gilead Sciences, Inc.; GlaxoSmithKline; Lantheus Medical Imaging Inc.; Novartis; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Taiho Oncology, Inc. This activity is supported by an independent educational grant from Astellas. This activity is supported by an education grant from Astellas and Seagen Inc. This activity is supported by a medical education grant from Karyopharm{\textregistered} Therapeutics. This activity is supported through an Independent Medical Education grant from Merck & Co., Inc. Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2022. All rights reserved.",
year = "2022",
month = mar,
doi = "10.6004/JNCCN.2022.0016",
language = "English (US)",
volume = "20",
pages = "225--234",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "3",
}